scispace - formally typeset
Search or ask a question
Institution

Hospital Universitario La Paz

HealthcareMadrid, Spain
About: Hospital Universitario La Paz is a healthcare organization based out in Madrid, Spain. It is known for research contribution in the topics: Population & Medicine. The organization has 8960 authors who have published 11499 publications receiving 191509 citations.


Papers
More filters
Journal ArticleDOI
Oriol Rodríguez-Leor1, Belén Cid-Álvarez, Armando Pérez de Prado, Xavier Rossello2, Soledad Ojeda3, Ana Serrador1, Ramón López-Palop, Javier Martín-Moreiras1, José Ramón Rumoroso, Angel Cequier4, Borja Ibanez1, Borja Ibanez2, Ignacio Cruz-González1, Rafael Romaguera4, Raúl Moreno1, Manuel Villa, Rafael Ruiz-Salmerón, Francisco Molano, Carlos Sánchez, Erika Muñoz-García, Luís Íñigo, Juan Herrador, Antonio Gómez-Menchero, Juan Caballero, Mérida Cárdenas, Livia Luciana Gheorghe, Jesús Oneto, Francisco J. Morales, Félix Valencia, José R. Ruiz, Jose A. Diarte, Pablo Avanzas, Juan Rondan, Vicente Peral, Lucía Vera Pernasetti, Julio Hernández, Francisco Bosa5, Pedro Luis Martín Lorenzo, Francisco Bermúdez Jiménez, José M. de la Torre Hernández, Jesús Jiménez-Mazuecos, Fernando Lozano, José Moreu, Enrique Novo, Javier Robles, Javier M. Moreiras, Felipe Fernández-Vázquez, Ignacio J. Amat-Santos, Joan Antoni Gómez-Hospital, Joan García-Picart6, Bruno García del Blanco, Ander Regueiro, Xavier Carrillo-Suárez, Helena Tizón, Mohsen Mohandes, Juan Casanova7, Víctor Agudelo-Montañez, Juan Muñoz, Juan Franco, Roberto del Castillo, Pablo Salinas8, Jaime Elízaga9, Fernando Sarnago, Santiago Jiménez-Valero10, Fernando Rivero, Juan Francisco Oteo, Eduardo Alegría-Barrero11, Ángel Sánchez-Recalde, Valeriano Ruiz, Eduardo Pinar, Ana Planas, Bernabé López Ledesma12, Alberto Berenguer, Agustín Fernández-Cisnal, Pablo Aguar, Francisco Pomar, Miguel Jerez, Francisco Torres, Ricardo García, Araceli Frutos, Juan Miguel Ruiz Nodar, Koldobika Garcia, Roberto Sáez, Alfonso Torres, Miren Tellería, Mario Sadaba, José Ramón López Mínguez, Juan Carlos Rama Merchán, Javier Fernández Portales, Ramiro Trillo, Guillermo Aldama, Saleta Fernández13, Melisa Santás, María P. Portero Pérez 
TL;DR: The number of STEMI patients treated during the current COVID-19 outbreak fell vs the previous year and there was an increase in the median time from symptom onset to reperfusion and a significant 2-fold increase inThe rate of in-hospital mortality.
Abstract: Introduction and objectives The COVID-19 outbreak has had an unclear impact on the treatment and outcomes of patients with ST-segment elevation myocardial infarction (STEMI). The aim of this study was to assess changes in STEMI management during the COVID-19 outbreak. Methods Using a multicenter, nationwide, retrospective, observational registry of consecutive patients who were managed in 75 specific STEMI care centers in Spain, we compared patient and procedural characteristics and in-hospital outcomes in 2 different cohorts with 30-day follow-up according to whether the patients had been treated before or after COVID-19. Results Suspected STEMI patients treated in STEMI networks decreased by 27.6% and patients with confirmed STEMI fell from 1305 to 1009 (22.7%). There were no differences in reperfusion strategy (> 94% treated with primary percutaneous coronary intervention in both cohorts). Patients treated with primary percutaneous coronary intervention during the COVID-19 outbreak had a longer ischemic time (233 [150-375] vs 200 [140-332] minutes, P Conclusions The number of STEMI patients treated during the current COVID-19 outbreak fell vs the previous year and there was an increase in the median time from symptom onset to reperfusion and a significant 2-fold increase in the rate of in-hospital mortality. No changes in reperfusion strategy were detected, with primary percutaneous coronary intervention performed for the vast majority of patients. The co-existence of STEMI and SARS-CoV-2 infection was relatively infrequent.

86 citations

Journal ArticleDOI
TL;DR: The results question the conventional general use of patient age as a high-risk factor in PTC and call for differentiation between patients with BRAF V600E and wild-type BRAF when applying age to risk stratification and management of PTC.
Abstract: PurposeFor the past 65 years, patient age at diagnosis has been widely used as a major mortality risk factor in the risk stratification of papillary thyroid cancer (PTC), but whether this is generally applicable, particularly in patients with different BRAF genetic backgrounds, is unclear. The current study was designed to test whether patient age at diagnosis is a major mortality risk factor.Patients and MethodsWe conducted a comparative study of the relationship between patient age at diagnosis and PTC-specific mortality with respect to BRAF status in 2,638 patients (623 men and 2,015 women) with a median age of 46 years (interquartile range, 35 to 58 years) at diagnosis and a median follow-up time of 58 months (interquartile range, 26 to 107 months). Eleven medical centers from six countries participated in this study.ResultsThere was a linear association between patient age and mortality in patients with BRAF V600E mutation, but not in patients with wild-type BRAF, in whom the mortality rate remained ...

86 citations

Journal ArticleDOI
29 Sep 2008-PLOS ONE
TL;DR: It is reported that silencing of a significant proportion of tumor suppressor genes in human embryonic and adult stem cells is associated with promoter DNA hypermethylation, indicating a role for DNA methylation in the control of gene expression in human stem cells and suggesting that the aberrant process in cancer could be understood as a defect in establishing an unmethylated promoter during differentiation.
Abstract: Developmental genes are silenced in embryonic stem cells by a bivalent histone-based chromatin mark. It has been proposed that this mark also confers a predisposition to aberrant DNA promoter hypermethylation of tumor suppressor genes (TSGs) in cancer. We report here that silencing of a significant proportion of these TSGs in human embryonic and adult stem cells is associated with promoter DNA hypermethylation. Our results indicate a role for DNA methylation in the control of gene expression in human stem cells and suggest that, for genes repressed by promoter hypermethylation in stem cells in vivo, the aberrant process in cancer could be understood as a defect in establishing an unmethylated promoter during differentiation, rather than as an anomalous process of de novo hypermethylation.

86 citations

Journal ArticleDOI
TL;DR: Atrial fibrillation had the same frequency and epidemiology in Spain as in other Western countries and antithrombotic therapy is underused by primary-care physicians and cardiologists.
Abstract: Introduction and objective. Atrial fibrillation is the most common arrhythmia seen in clinical practice. The objective of this study was to know the frequency of atrial fibrillation and the characteristics of patients with atrial fibrillation in the Cardiotens study. Material and method. A cross-section study with systematic selection of the study sample. All 32,051 outpatients seen on the same day by 1,159 physicians specialized in primary-care (79%) and cardiology (21%) were prospectively added to a database including history of cardiac disease (heart failure, coronary disease or atrial fibrillation), blood pressure, and ongoing treatment. Results. Atrial fibrillation was present in 25% of patients with previous cardiovascular disease (6,194 patients), the prevalence being 4.8% (1,540/32,051) of the study population. Atrial fibrillation was more frequent in females 29%, (810/2,837) than in males, 22% (730/3,367), p < 0.005). Atrial fibrillation was present in 33% (469/1,420) of patients with heart failure and in 12% (387/3,226) of those with coronary heart disease. Arterial hypertension was diagnosed in 25% of the patients with atrial fibrillation. Only 33% of them were treated with oral anticoagulants (41% of the patients seen by cardiologists and 26% by primary-care physicians, p < 0.005). The antiarrhythmic drug most often used was digoxin (36%). Conclusions. Atrial fibrillation had the same frequency and epidemiology in Spain as in other Western countries. Antithrombotic therapy is underused by primary-care physicians and cardiologists.

86 citations

Journal ArticleDOI
TL;DR: Fish and its derived products play an important role in human nutrition, but they may also be a potent food allergen and those from the Tunidae and Xiphiidae families appear to be the least allergenic.
Abstract: Fish and its derived products play an important role in human nutrition, but they may also be a potent food allergen. Fish can be an ingested, contact, and inhalant allergen. Gad c I, a Parvalbumin, the major allergen in codfish, is considered as fish and amphibian pan-allergen. Prevalence of fish allergy appears to depend on the amount of fish eaten in the local diet. In Europe, the highest consumption occurs in Scandinavian countries, Spain and Portugal. In Spain, fish is the third most frequent allergen in children under 2 yr of age after egg and cow's milk. An adverse reaction to fish may be of non-allergic origin, due to food contamination or newly formed toxic products, but the most frequent type of adverse reactions to fish are immunologic-mediated reactions (allergic reactions). Such allergic reactions may be both IgE-mediated and non-IgE-mediated. Most cases are IgE-mediated, due to ingestion or contact with fish or as a result of inhalation of cooking vapors. Some children develop non-IgE-mediated type allergies such as food protein induced enterocolitis syndrome. The clinical symptoms related to IgE-mediated fish allergy are most frequently acute urticaria and angioedema as well as mild oral symptoms, worsening of atopic dermatitis, respiratory symptoms such as rhinitis or asthma, and gastrointestinal symptoms such as nausea and vomiting. Anaphylaxis may also occur. Among all the species studied, those from the Tunidae and Xiphiidae families appear to be the least allergenic.

86 citations


Authors

Showing all 9020 results

NameH-indexPapersCitations
Jaakko Tuomilehto1151285210682
Vincent Soriano8776234084
Lina Badimon8668235774
Francisco J. Blanco8478933319
Michael A. Gatzoulis8247832562
Jose Lopez-Sendon8146041809
Victor Moreno8063531511
Joaquín Dopazo7539624790
Fernando Rodríguez-Artalejo7451223296
José R. Banegas7442128249
Michael Becker7231718189
Gianfranco Ferraccioli7040226515
Maria-Victoria Mateos6648024278
Manuel Romero-Gómez6442019006
Eulogio García6327015354
Network Information
Related Institutions (5)
Carlos III Health Institute
30K papers, 849K citations

84% related

University of Navarra
26.6K papers, 747.2K citations

83% related

Autonomous University of Barcelona
80.5K papers, 2.3M citations

80% related

University of Barcelona
108.5K papers, 3.7M citations

80% related

University Medical Center Groningen
30.3K papers, 967K citations

80% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
202322
202272
20211,335
20201,186
2019889
2018670